Aeolus AEOL 10150 study confirms ability to rescue skin from deleterious effects of CEES

Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) reported that researchers from National Jewish Health and the University of Colorado Anschutz Medical Campus have completed studies demonstrating that AEOL 10150 provides statistically significant protection of the skin in the 2-chloroethyl-ethylsulfide (CEES; half mustard) model of mustard gas exposure in mice and in a human cell culture model. Data were presented at the 4^th Annual CounterACT Countermeasures Against Chemical Threats Network Research Symposium in San Francisco. There are currently no effective treatments for mustard gas exposure and AEOL 10150 is a major focus of a sponsored research grant awarded by the NIH Counteract program to National Jewish Health to identify an effective treatment. Sulfur mustards have been used in warfare since WWI and still pose a significant threat to civilian and military personnel. Mustard gas exposure can cause significant blistering of the skin as well as respiratory injury and fibrosis.

“Given the significant effects we have seen in studies of the compound's ability to protect the lungs from mustard vapor exposure, it appears that AEOL 10150 may have the ability to protect both the skin and lungs from mustard gas exposure.”

"This study confirms AEOL 10150's ability to rescue the skin from the deleterious effects of CEES, and we are eager to expand our testing of the compound in CEES as well as whole mustard gas exposure," stated Brian Day, PhD, Professor and Vice Chair of Research, the Department of Medicine at National Jewish Health and Investigator of the CounterACT Center of Excellence in Denver. "Given the significant effects we have seen in studies of the compound's ability to protect the lungs from mustard vapor exposure, it appears that AEOL 10150 may have the ability to protect both the skin and lungs from mustard gas exposure."